Prevention of recurrences of papillary bladder tumours was attempted in 93 patients through various measures: addition of Trenimon to the irrigating fluid during and/or after TUR; intravesical instillation of thiotepa, 5-FU, daunomycin or SP-I, administration of various drugs intravenously (mitomycin C, 5-FU) or orally (cyclo-phosphamide, Trenimon, hydroxyurea, methotrexate, procarbazine, SP-G, ascorbic acid). Intravesical instillation yielded the best results, thiotepa appearing to be the drug of choice. Recurrent tumours appeared only after the instillations had been discontinued. A more prolonged treatment is therefore advocated. The addition of drugs to the irrigation fluid has also proved of some value. Among oral drugs, hydroxyurea, procarbazine and methotrexate, displaying a high urinary excretion, appear very promising although the experience is still limited. The association of topical thiotepa with i. v. mitomycin C and 5-FU was employed in 6 cases with muscular invasion, with 2 recurrences and only transient toxic effects. No untoward effects were observed using the other preventive methods.

Keywords:
Bladder papilloma, Thiotepa, Hydroxyurea, Methotrexate, Procarbazine
This content is only available via PDF.
© 1971 S. Karger AG, Basel
1971
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.